109 related articles for article (PubMed ID: 12124412)
21. Pitting phosphate transport inhibitors against vascular calcification.
Demer LL; Tintut Y
Circ Res; 2006 Apr; 98(7):857-9. PubMed ID: 16614308
[No Abstract] [Full Text] [Related]
22. [Crosstalk between the immune and skeletal system].
Takayanagi H
Ryumachi; 2003 Oct; 43(4):624-31. PubMed ID: 14598653
[No Abstract] [Full Text] [Related]
23. [Recent advances in basic research of bone metabolism].
Inoue D; Matsumoto T
Nihon Rinsho; 2002 Mar; 60 Suppl 3():25-33. PubMed ID: 11979916
[No Abstract] [Full Text] [Related]
24. [Future therapies for metabolic bone diseases. New concepts and targets].
Nemec K; Schubert-Zsilavecz M
Pharm Unserer Zeit; 2001; 30(6):548-52. PubMed ID: 11715689
[No Abstract] [Full Text] [Related]
25. Canonical Wnt signaling in osteoblasts is required for osteoclast differentiation.
Glass DA; Karsenty G
Ann N Y Acad Sci; 2006 Apr; 1068():117-30. PubMed ID: 16831912
[TBL] [Abstract][Full Text] [Related]
26. Osteoclast diseases.
Helfrich MH
Microsc Res Tech; 2003 Aug; 61(6):514-32. PubMed ID: 12879419
[TBL] [Abstract][Full Text] [Related]
27. Genetic regulation of osteoclast development and function.
Teitelbaum SL; Ross FP
Nat Rev Genet; 2003 Aug; 4(8):638-49. PubMed ID: 12897775
[TBL] [Abstract][Full Text] [Related]
28. The osteoprotegerin/osteoprotegerin ligand family: role in inflammation and bone loss.
Yeung RS
J Rheumatol; 2004 May; 31(5):844-6. PubMed ID: 15124240
[No Abstract] [Full Text] [Related]
29. Lack of mutations in the RANK gene in Spanish patients with Paget disease of bone.
Marco-Mingot M; San-Millán JL; Wuyts W; Bachiller-Corral J; Van Hul W; Morales-Piga AA
Clin Genet; 2001 Jul; 60(1):86-8. PubMed ID: 11531977
[No Abstract] [Full Text] [Related]
30. Cytokines, osteoprotegerin, and RANKL in vitro and histomorphometric indices of bone turnover in patients with different bone diseases.
Siggelkow H; Eidner T; Lehmann G; Viereck V; Raddatz D; Munzel U; Hein G; Hüfner M
J Bone Miner Res; 2003 Mar; 18(3):529-38. PubMed ID: 12619938
[TBL] [Abstract][Full Text] [Related]
31. Transcription Factor Decoy (TFD) as a novel approach for the control of osteoclastic resorption.
Cozzani M; Giovannini I; Naccari R; Penolazzi L; Lambertini E; Borgatti M; Piva R; Gambari R; Siciliani G
Prog Orthod; 2005; 6(2):238-47. PubMed ID: 16276433
[No Abstract] [Full Text] [Related]
32. [Osteoclast function is regulated by neighbouring osteoblasts. Osteoprotegerin, RAND and RANK ligand constitute a unique regulatory system for bone resorption with important pathophysiological and therapeutic aspects].
Ueland T; Bollerslev J; Mosekilde L
Ugeskr Laeger; 2002 Jul; 164(27):3526-30. PubMed ID: 12116680
[TBL] [Abstract][Full Text] [Related]
33. RANKing the importance of measles virus in Paget's disease.
Ross FP
J Clin Invest; 2000 Mar; 105(5):555-8. PubMed ID: 10712423
[No Abstract] [Full Text] [Related]
34. [The cytokine system of bone tissue].
Stilgren LS; Abrahamsen B; Abdallah BM; Jørgensen NR
Ugeskr Laeger; 2005 Feb; 167(8):874-8. PubMed ID: 15789838
[No Abstract] [Full Text] [Related]
35. [Effects of 1,25-dihydroxyvitamin D3 on the expressions of osteoprotegerin and receptor activator of NF-kappaB ligand in mouse osteoblasts].
Tian QX; Huang GY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Aug; 26(4):418-22. PubMed ID: 15379268
[TBL] [Abstract][Full Text] [Related]
36. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing.
Kon T; Cho TJ; Aizawa T; Yamazaki M; Nooh N; Graves D; Gerstenfeld LC; Einhorn TA
J Bone Miner Res; 2001 Jun; 16(6):1004-14. PubMed ID: 11393777
[TBL] [Abstract][Full Text] [Related]
37. Rheumatic diseases: the effects of inflammation on bone.
Walsh NC; Crotti TN; Goldring SR; Gravallese EM
Immunol Rev; 2005 Dec; 208():228-51. PubMed ID: 16313352
[TBL] [Abstract][Full Text] [Related]
38. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin.
Collin-Osdoby P
Circ Res; 2004 Nov; 95(11):1046-57. PubMed ID: 15564564
[TBL] [Abstract][Full Text] [Related]
39. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.
Theoleyre S; Wittrant Y; Tat SK; Fortun Y; Redini F; Heymann D
Cytokine Growth Factor Rev; 2004 Dec; 15(6):457-75. PubMed ID: 15561602
[TBL] [Abstract][Full Text] [Related]
40. Association of the osteoprotegerin gene polymorphisms with bone mineral density in postmenopausal women.
Arko B; Prezelj J; Kocijancic A; Komel R; Marc J
Maturitas; 2005 Jul; 51(3):270-9. PubMed ID: 15978970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
